Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS.NS)
INR 56.84
(0.0%)
INR 56.84
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.25 Million | -12.81 Million | -44.93 Million | 54.76 Million | 28.57 Million | 6.88 Million |
| Net Income | 46.83 Million | 60.15 Million | 100.27 Million | 83.01 Million | 72.42 Million | 89.86 Million |
| Depreciation & Amortization | 16.98 Million | 15.73 Million | 19.88 Million | 9.2 Million | 8.93 Million | 10.08 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -67.75 Million | -94.58 Million | -149.18 Million | -45.12 Million | -55.63 Million | -92.85 Million |
| Other non-cash items | 10.07 Million | 5.88 Million | -15.9 Million | 7.67 Million | 2.84 Million | -200.7 Thousand |
| Investing Cash Flow | -17.02 Million | 4.41 Million | -21.96 Million | -28.79 Million | -9.18 Million | -12.28 Million |
| Investments in PPE | -7.22 Million | -10.44 Million | -22.01 Million | -28.79 Million | -9.18 Million | -12.28 Million |
| Acquisitions | - | -14.85 Million | 46 Thousand | - | - | - |
| Investment purchases | -9.8 Million | -4.18 Million | -23.88 Million | - | - | - |
| Sales/Maturities of investments | - | 19.03 Million | -46 Thousand | - | - | - |
| Other Investing Activities | -9.8 Million | 14.85 Million | 23.93 Million | - | - | - |
| Financing Cash Flow | 43.16 Million | 13.54 Million | 62.31 Million | -24.5 Million | -18.04 Million | -24.81 Million |
| Debt repayment | -62.92 Million | -235.55 Million | -39.78 Million | -1.29 Million | -17.52 Million | -129.36 Million |
| Dividends payments | - | - | - | - | - | -2.33 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 106.58 Million | - | 82.32 Million | - | - | - |
| Other Financing Activities | -490 Thousand | 249.09 Million | 19.78 Million | -23.21 Million | -526.05 Thousand | 106.89 Million |
| Accounts receivables | 53.02 Million | -534.96 Million | 257.29 Million | -658.79 Million | 96.11 Million | -104.47 Million |
| Accounts payables | 16.11 Million | 176.7 Million | -6.78 Million | 325.9 Million | 404.71 Million | -403 Million |
| Inventory | -58.56 Million | -151.35 Million | 47.76 Million | -14.64 Million | 42.54 Million | -64.75 Million |
| Other working capital | -78.32 Million | 415.03 Million | -447.45 Million | 302.41 Million | -599 Million | 479.38 Million |
| Cash at beginning of period | 7.05 Million | 1.91 Million | 6.49 Million | 5.02 Million | 3.68 Million | 33.89 Million |
| Cash at end of period | 15.94 Million | 7.05 Million | 1.91 Million | 6.49 Million | 5.02 Million | 3.68 Million |
| Capital Expenditure | -7.22 Million | -10.44 Million | -22.01 Million | -28.79 Million | -9.18 Million | -12.28 Million |
| Effect of forex changes on cash | - | - | -106.00 | -1.00 | 2.00 | 7.34 |
| Net cash flow / Change in cash | 8.88 Million | 5.13 Million | -4.57 Million | 1.46 Million | 1.33 Million | -30.2 Million |
| Free Cash Flow | -24.47 Million | -23.25 Million | -66.94 Million | 25.97 Million | 19.38 Million | -5.39 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 12.39 Million | 46.83 Million | 21.52 Million | 10.22 Million | 7.84 Million | 7.24 Million |
| Depreciation & Amortization | - | 16.98 Million | - | 4.72 Million | 4.09 Million | 4.16 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -67.75 Million | - | - | - | - |
| Other non-cash items | -12.39 Million | 10.07 Million | -21.52 Million | -10.22 Million | -7.84 Million | -7.24 Million |
| Investing Cash Flow | - | -17.02 Million | - | - | - | - |
| Investments in PPE | - | -7.22 Million | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -9.8 Million | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | -9.8 Million | - | - | - | - |
| Financing Cash Flow | - | 43.16 Million | - | - | - | - |
| Debt repayment | - | -62.92 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 106.58 Million | - | - | - | - |
| Other Financing Activities | - | -490 Thousand | - | - | - | - |
| Accounts receivables | - | 53.02 Million | - | - | - | - |
| Accounts payables | - | 16.11 Million | - | - | - | - |
| Inventory | - | -58.56 Million | - | - | - | - |
| Other working capital | - | -78.32 Million | - | - | - | - |
| Cash at beginning of period | - | 7.05 Million | - | 11.67 Million | 3.47 Million | 7.05 Million |
| Cash at end of period | - | 15.94 Million | - | 21.11 Million | 11.67 Million | 15.37 Million |
| Capital Expenditure | - | -7.22 Million | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | 8.88 Million | - | 9.44 Million | 8.19 Million | 8.32 Million |
| Free Cash Flow | - | -24.47 Million | - | 9.44 Million | 8.19 Million | 8.32 Million |
SUGALDAM
SHIVAGR
HAR
EKH
3611
PGM